The Children’s Hospital of Philadelphia (CHOP) presented a new study exploring the potential to treat mill-related eosinophilic esophagitis (EoE) via epicutaneous immunotherapy (EPIT) reports Laura Genn of MD.
A double-blind study randomly assigned 20 children aged 4-17 years old with milk-induced EoE to either the Viaskin mil patch group (n=15) or placebo group (n =5). Ms. Genn reported that the CHOP investigators assessed the patients sensitivity differences to the allergen—those with decreased sensitivity could enter an open-label phase. The final phase gradually introduced milk into the patient’s diets for 11 months with ongoing EPIT therapy.
Genn reported that unfortunately, the results were reduced by a “compliance issue” as reported by lead author Jonathan M. Spergel, MD, PhD. He told MD Magazine that “an improved practice would have been to simplify the dietary restrictions” as several of the patients didn’t follow their prescribed diet as designed by the protocol. The study’s formal title “Efficacy of Epicutaneous Immunotherapy in Children with Milk-Induced Eosinophilic Esophagitis” and was published online in Clinical Gastroenterology and Hepatology.
What is EPIT
Epicutaneous immunotherapy (EPIT) is a potential new class of immunotherapy that works by delivering the biologically active compound to the immune system through intact skin.
Jonathan M. Spergel, MD, PhDSource: MD Mag